Amgen (AMGN) News Today

Amgen Inc. (NASDAQ:AMGN) shares are moving after a mix of strong second-quarter results, analyst price-target revisions and updated forecasts. Investors are weighing upbeat earnings and pipeline commentary against some downward estimate adjustments. Here’s what’s driving the action:

• Positive Sentiment: Citigroup raised its price target on AMGN from $305 to $310 (neutral rating). Citigroup Price Target
• Positive Sentiment: Morgan Stanley lifted its target from $330 to $333 with an “equal weight” rating. Morgan Stanley Report
• Positive Sentiment: Amgen beat Q2 EPS estimates by $0.81, reporting $6.02/share vs. $5.21 expected and $9.2 billion in revenue vs. $8.9 billion. Q2 Earnings Beat
• Positive Sentiment: Benzinga highlights a “beat-and-raise” quarter and a strong late-stage pipeline supporting future growth. Beat-and-Raise Article
• Positive Sentiment: Zacks notes Q2 earnings and sales beat estimates and slightly raised its 2025 outlook. Zacks Earnings Recap
• Positive Sentiment: William Blair raised its FY2025 EPS estimate to $20.86 (from $20.71) and maintained an “Outperform” rating, citing stronger margin trends.
• Positive Sentiment: GuruFocus recap of the Q2 earnings call highlights 9% product-sales growth and a robust late-stage pipeline. GuruFocus Call Highlights
• Positive Sentiment: A biotech-sector roundup notes Amgen among firms that beat Q2 estimates and raised guidance.
• Neutral Sentiment: Amgen issued FY2025 EPS guidance of $20.20–21.30 (vs. $20.889 consensus) and revenue guidance of $35.0 billion–$36.0 billion (vs. $35.3 billion est.). Guidance Update
• Neutral Sentiment: Yahoo Finance video lists Amgen among trending tickers alongside NRG Energy and Arista Networks. Trending Tickers
• Negative Sentiment: UBS cut its price target from $326 to $317, keeping a “neutral” stance. UBS Price Target
• Negative Sentiment: Leerink Partners reduced Q3 EPS estimates to $5.13 from $5.40, reflecting near-term margin pressure.
• Negative Sentiment: MSN reports that despite the beat-and-raise, the stock stumbled on lingering pipeline and macro concerns. MSN Article
• Negative Sentiment: Benzinga notes shares sank as investors eyed uncertainty around the MariTide asset deal. MariTide Article
• Negative Sentiment: Seeking Alpha argues Amgen still isn’t a buy, citing valuation and competitive risks. SA Analysis

Overall, strong Q2 results and upward estimate revisions are underpinning positive momentum, while mixed guidance and select analyst downgrades are capping gains.